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c-myc antisense oligonucleotide treatment ameliorates murine slower progression than ARPKD, which usually affects
ARPKD. newborns or young children. ARPKD can cause massive
Background. Overexpression of c-myc is postulated to play bilateral enlargement of the kidneys. Most individualsa role in the pathogenesis of polycystic kidney disease (PKD).
with ARPKD who survive the neonatal period developc-myc expression is increased in all rodent models of PKD
renal failure.that have been examined as well as in human ADPKD. To
determine whether overexpression of renal c-myc contributes The human ARPKD gene is located on chromosome
to renal cyst formation, C57BL/6J-cpk litters (an animal model 6 [1], but has not yet been cloned. Nonetheless, a number
of ARPKD) were treated with an antisense oligomer (ASO) of mouse models of ARPKD exist to study this conditionto c-myc mRNA.
[2]. The C57BL/6J mouse homozygous for the congenitalMethods. Injections of 30 g of a c-myc ASO were given
polycystic kidney (cpk) gene mutation is one of the mostto C57BL/6J-cpk litters on postnatal days 7–20. Control mice
received either sham injections or injections of an equal amount widely utilized models of ARPKD [3, 4]. While the cpk
of a scrambled ASO. At 20 days, kidney weight, body weight, gene is not analogous to the human ARPKD gene, the
serum urea nitrogen (SUN), hematocrit, and renal concentra- PKD in this well characterized mouse model exhibitstion of ASO were determined. In kidney, c-Myc and PCNA
severe bilateral renal cysts in a pattern very similar toprotein were assessed by immunoblotting and steady state lev-
human ARPKD. The collecting duct cysts are the pre-els of renal RNA for c-myc, EGF, SGP-2, and histone H4
were assessed by northern blot hybridization. c-Myc and PCNA dominant pathology and replace the normal renal paren-
proteins were localized by immunohistochemistry. chyma leading to morbid uremia by approximately four
Results. Cystic mice treated with the c-myc ASO had a de- weeks of age.creased relative kidney weight, improved renal function, and
C57BL/6J-cpk/cpk mice have previously been showna reduced amount of cystic change compared with sham and
to overexpress renal c-myc mRNA [5, 6]. The c-mycscrambled ASO controls. The abnormal expression of several
PKD related proteins and mRNAs were partially reversed by mRNA is overexpressed in epithelia from cystic as well
c-myc antisense treatment. c-myc staining appeared to be re- as normal sized tubules [7]. Renal c-myc mRNA is also
duced in the noncystic tubules. Treatment with the c-myc ASO overexpressed in other rodent models of PKD such asdid not cause a reduction in hematocrit or total body weight
Han:SPRD-cy/cy rats [8], CD-1-pcy/pcy mice [9], andindicating that the beneficial effects were not due to a general-
BALB/c-cpk/cpk mice [10]. Interestingly, mice overex-ized inhibition of cell proliferation in rapidly growing tissue.
Conclusions. c-Myc appears to play a role in the cystogenesis pressing a c-myc transgene develop PKD and die of renal
of cpk-induced murine PKD and antisense targeting the over- failure by six weeks to three months of age [11, 12].
expression of c-myc partially ameliorated the renal changes. Human ADPKD kidney also has been shown to overex-
press c-myc mRNA [13]. Therefore, renal c-myc overex-
pression must play an important role in renal cystogen-INTRODUCTION
esis since it is always associated with PKD. To determinePolycystic kidney disease (PKD) is a major cause of
if increased c-myc mRNA expression contributes to PKDend stage renal disease in humans. PKD is characterized
development, C57BL/6J-cpk/cpk mice were treated withby severe dilation of renal tubules and can be inherited
a c-myc antisense oligomer (ASO) (AVI BioPharma, Cor-as an autosomal dominant (AD) or autosomal recessive
vallis, OR).(AR) trait. In humans, ADPKD has a later onset and
MATERIALS AND METHODSKey words: polycystic kidney disease, C57BL/6J-cpk/cpk mice, c-myc,
antisense oligonucleotide, EGF, clusterin (SGP-2), PCNA. C57BL/6J-cpk/mice (colony established at KU Med-
ical Center, stock originally obtained from Jackson Lab- 2002 by the International Society of Nephrology
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oratory, Bar Harbor, ME) were bred to produce the tors (catalog number 1836170, Boehringer Mannheim,
Mannheim, Germany). Protein was isolated and pro-normal (/ or cpk/) and cystic (cpk/cpk) mice used
in this study. Litters of C57BL/6J- cpk mice received i.p. cessed for western blot analysis by standard techniques.
Protein samples were separated on a 12.5% SDS/acryl-injections of 4.3 nmoles (30 g) per day of the c-myc
ASO (AVI-4126, AVI BioPharma, Corvallis, OR) on amide gel with a 6% SDS/acrylamide stacking gel at 33
mA for 14 h. The gels were soaked in transfer bufferpostnatal days 7 through 20. A few litters were treated
with higher (14.3 nmoles; 100 g) or lower (1.4 nmoles; (192 mM glycine, 25 mM Tris base, and 10% methanol,
pH 8.3) for 20 minutes and transferred to Immobilon-P10 g) dosages of the c-myc ASO. The c-myc ASO had
a phosphorodiamidate Morpholine backbone with a se- transfer membranes (Millipore Corporation, Bedford,
MA, at 80 volts for 80 min). The membranes were soakedquence of 5-ACG TTG AGG GGC ATC GTC GC-3.
As controls, mice were either sham injected or given an briefly in methanol and dried at 40C. Membranes were
rehydrated briefly in methanol, rinsed in wash bufferequal amount of a scrambled ASO (ACT GTG AGG
GCG ATC GCT GC). These mice were sacrificed four (PBS with 0.3% Tween 20) and incubated in blocking
buffer (PBS, 0.3% Tween 20 and 3% powdered milk)hours after their last injection. Control, scrambled and
c-myc ASO (AVI BioPharma, Corvallis, OR) treated for 30 minutes. Membranes were incubated for one hour
with primary antibodies to: c-Myc (catalog number sc-C57BL/6J-cpk litters were anesthetized (65 mg/kg so-
dium pentobarbital, i.p.) and sacrificed at 20 days of age. 764, Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
glucocorticoid receptor (catalog number sc-1004, SantaTotal body weight, total kidney weight and kidney weight
as a percent of body weight were determined. Blood was Cruz Biotechnology, Inc., Santa Cruz, CA) and PCNA
(catalog number sc-7907, Santa Cruz Biotechnology,collected from the heart, hematocrit was measured, and
serum was used to assess renal function. SUN was deter- Inc., Santa Cruz, CA). The membranes were washed
three times for 5 minutes with wash buffer and incubatedmined utilizing a colorimetric assay (catalog number
640-A, Sigma Diagnostics, St. Louis, MO). The left kid- for 30 minutes with the appropriate horseradish peroxi-
dase (HRP) conjugated secondary antibody. Membranesney was removed, weighed, snap frozen in liquid nitro-
gen, and stored at –80C until processed for RNA isola- were rinsed again with wash buffer and incubated with
ECL detection reagent (Promega, Madison, WI) fol-tion. The animals were then perfusion fixed with 4%
paraformaldehyde in 0.1 M phosphate buffer through a lowed by autoradiography using Kodak Bio Max film.
catheter placed in the left ventricle. The right kidney
Extraction and analysis of renal c-myc ASOwas processed for paraffin embedment and sections were
stained with periodic acid Schiffs reaction or immuno- 500 ng of an internal standard (AVI-0-1-22-242, AVI
BioPharma, Corvallis, OR; a 15 mer phosphorodiami-stained for c-Myc.
date Morpholine oligomer whose sequence is derived
Immunohistology from a 5 truncation of the c-myc ASO) was mixed with
a 500 L aliquot of kidney lysate prepared in RIPAParaffin sections of kidneys from c-myc ASO treated
and untreated 20 day-old normal and cystic C57BL/6J- buffer. An equal volume of methanol was added, and
the resulting precipitate was centrifuged for 10 minutes.cpk mice were processed for c-Myc immunohistochemis-
try. After endogenous peroxidase activity was quenched The supernatant was collected, the pellet was washed
with 100 L of 0.025 M Tris buffer (pH 9.0) and recentri-with methanolic peroxide, the sections were treated with
normal goat blocking serum. Kidney sections were incu- fuged. The resulting supernatants were collected, heated
at 70C for 10 minutes and recentrifuged. The superna-bated with a primary antibody to c-Myc (1:25, catalog
number sc-764, a rabbit polyclonal antibody to human tant was lyophilized following the addition of 100 L of
0.025 M Tris buffer (pH 9.0). The resulting residue wasc-Myc, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
18 hours at 4C). The bound antibody was visualized reconstituted with 100 L of a 5-fluorescein labeled
DNA (FDNA, Hybridon, Inc., MA) solution (0.2 OD’susing an avidin biotin complex method (Vector Labora-
tories, Inc., Burlingame, CA) with nickel-enhanced DAB in 100 L of 0.025 M Tris buffer). The FDNA has a
complementary sequence to that of the c-myc ASO andas the chromagen. Negative control sections were pro-
cessed in an identical manner, except normal rabbit se- forms a stable duplex. The entire sample was injected
and analyzed by HPLC (Varian 9010 HPLC pump, Palorum replaced the primary antibody.
Alto, CA, attached to a Rainin AI-200 autosampler and
Western blot analysis a Varian 9075 Fluorescence detector connected to a
DNAPac PA-100 anion exchange column, Dionex Corp.,Fresh kidneys from c-myc ASO treated and untreated
C57BL/6J-cpk/cpk mice were removed at 21 days and Sunnyvale, CA). A binary gradient (10% B at 0 min to
45% B at 20 min) consisting of 0.025 M Tris buffer (pHimmediately homogenized in Radio Immuno Precipita-
tion Assay (RIPA) buffer (1X PBS, 1% Nonidet P-40, 9.0) as mobile phase A and 0.025 M Tris buffer (pH 9.0)/
1 M NaCl as mobile phase B was used to achieve the0.5% deoxycholic acid, 0.2% SDS) with protease inhibi-
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chromatographic separation. The fluorescence excitation renal function (Table 1). Total body weight and hemato-
crit were not affected by the c-myc ASO treatment (Ta-and emission wavelengths were set at 494 nm and 518
ble 1), suggesting that ASO treatment did not signifi-nm, respectively. The amount of the c-myc ASO present
cantly affect normal highly proliferative, extrarenalin the kidney lysate samples was determined using a
processes. While ASO treatment slowed renal enlarge-standard curve generated by running a series of c-myc
ment, the C57BL/6J-cpk/cpk kidneys from treated miceASO solutions containing the internal standard.
still exhibited significant cystic pathology (Fig. 1). No
renal changes were seen in normal C57BL/6J mice fol-RNA isolation and northern hybridization
lowing c-myc ASO treatment (data not shown).RNA was extracted and purified from kidneys of 20
c-myc mRNA was clearly over-expressed in the cysticday-old normal and cystic mice as well as 20 day-old
kidney. This over-expression was unaltered by c-mycc-myc ASO and scrambled oligomer treated normal and
ASO treatment (Fig. 2). However, treatment inhibitedcystic mice using the acid guanidinium thiocyanate-phe-
translation of the c-myc mRNA into c-Myc protein asnol-chloroform extraction method as previously de-
evinced by lower c-Myc protein (a 59% reduction byscribed [14]. The frozen kidneys were homogenized in
western blot analysis, Fig. 3). EGF mRNA is highly ex-
Tri-Reagent (Molecular Research Center, Inc., Cincin-
pressed in normal renal distal tubules, but severely di-
nati, OH) and RNA was isolated according to the manu- minished in the cystic kidney [17]. Following c-myc ASO
facturer’s instructions. The RNA was separated on a 1% treatment, EGF mRNA expression was increased nearly
agarose/formaldehyde gel via electrophoresis, with each twelve fold in the cystic kidney (Fig. 2). Messenger RNA
lane containing 10 g of total renal RNA. The RNA for SGP-2, or clusterin, a marker of immature collecting
was then transferred overnight to a Zetabind membrane duct, was over-expressed in cystic versus normal kidney,
(Cuno, Inc., Meriden, CT), and stained with methylene but was decreased 40% after c-myc ASO treatment (Fig.
blue to ensure equivalent amounts of RNA in each lane. 2). Increased EGF mRNA and decreased SGP-2 mRNA
The RNA was baked (2 hours at 80C) and hybridized expression indicate that c-myc ASO treatment led to
overnight at 65C in Church’s buffer [15] (1% BSA and an increased maturation of both the distal tubules and
7% SDS in 0.5 M sodium phosphate with 1 mM EDTA) collecting ducts, respectively. mRNA for Histone H4, a
with 32P-labeled cDNA probes (random prime labeling marker associated with increased cell proliferation, was
method, Rediprime II, Amersham Pharmacia Biotech, over-expressed in cystic compared to normal kidney.
Arlington Heights, IL). The probes identified c-myc [7], c-myc ASO treatment did not significantly reduce the
clusterin (SGP-2) [16], prepro epidermal growth factor Histone H4 message level in cystic kidney (Fig. 3). How-
ever, ASO treatment was associated with a 30% decrease[17], and Histone H4 [4] mRNAs. Hybridized northern
in PCNA, a protein marker of cell proliferation (Fig. 3).blots were washed for 10 minutes each at 65C; twice in
c-Myc protein was elevated in the cystic compared toWash Buffer A (0.5% BSA and 5% SDS in 40 mM
normal kidneys [5] (Figs. 3 and 4). By immunohistochem-sodium phosphate with 1 mM EDTA), and four times
istry, the c-Myc was localized to the nuclei of epithelialin Wash Buffer B (1% SDS in 40 mM sodium phosphate
cells lining cystic and noncystic tubules. After c-mycwith 1 mM EDTA). Autoradiography was used to visual-
ASO treatment, the lower c-Myc protein levels appearize the relative expression of mRNA. Specific mRNA
to be due largely to a reduction in c-Myc protein in thewas quantitated using densitometry of the autoradio-
noncystic tubules (Fig. 4A and C). Therefore, abnormali-graph. All of the northern blot hybridization studies were
ties typically seen in noncystic tubules of the cystic kidneyperformed in duplicate with different sets of RNAs.
were reduced by c-myc ASO treatment.
Statistical analysis
Quantification of renal c-myc ASO
Statistical analysis of SUN, total body weight, kidney
The c-myc ASO was detected in kidney lysate at a
weight as a percent of body weight, and hematocrit were concentration of 0.47 M one hour after the final injec-
performed using analysis of variance (ANOVA) (P  tion in animals treated for 14 days with 4.3 nmoles (30g)
0.05) with the aid of MINITAB software (State College, per day. There was no phosphorodiamidate morpholine
PA). Data are presented as mean  SEM. oligomer detected in kidney lysate from 20 day-old un-
treated C57BL/6J-cpk mice which served as a negative
control.RESULTS
Effects of c-myc morpholine antisense Dose response
oligomer treatment Higher (14.3 nmoles; 100 g) and lower (1.4 nmoles;
The c-myc ASO treatment significantly reduced the 10 g) dosages of the c-myc ASO also ameliorated the
PKD. Relative kidney weight as well as SUN levels werecystic renal enlargement and inhibited the decline in
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Table 1. Effect of treatment of C57BL/6J-cpk mice with c-myc antisense oligonucleotide (Mean  SEM, N)
Control c-myc antisense Scrambled antisense
Group phenotype Normal Cystic Normal Cystic Normal Cystic
Kidney weight 1.480.03 21.681.88 1.640.02 11.910.45a 1.540.02 17.930.65
(as a percent of (14) (11) (15) (5) (12) (8)
total body weight)
Serum urea nitrogen 16.31.0 62.46.8 17.50.7 38.43.2a 20.30.7 59.84.8
mg/dL (15) (11) (15) (5) (11) (8)
Total body weight 10.50.35 10.60.65 10.10.42 9.00.40 9.530.34 10.00.30
grams (15) (11) (15) (5) (12) (8)
Hematocrit %b 30.91.12 23.82.35 31.70.45 22.01.68 30.51.01 25.60.98
(15) (11) (11) (5) (10) (8)
a P  0.05 for difference of treated from control/scrambled value within the phenotype
b P  0.05 for difference between cystic and normal, but not with treatment
Fig. 1. Light micrographs of 20 day-old control and c-myc ASO treated
C57BL/6J-cpk cystic kidneys. Compared with (a, b ) control cystic kid-
ney, (c, d ) c-myc ASO treated cystic kidney exhibits an increased
amount of normal renal parenchyma. a, b: 8X; c, d: 30X.
reduced to a similar extent to that observed after treat-
ment with 4.3 nmoles (30 g) of c-myc ASO. Total body
weight and hematocrit levels were also unaffected by
these dosages of c-myc ASO (data not shown).
Fig. 2. Renal mRNA expression in 20 day-old control, scrambled oligo-
nucleotide and c-myc ASO treated normal and cystic C57BL/6J-cpkDISCUSSION
mice. The c-myc, histone H4, and SGP-2 messages were overexpressed
in cystic compared to normal kidney. c-myc ASO treatment did notThe c-myc gene, located on mouse chromosome 15,
alter c-myc or histone H4 mRNA expression, but did decrease SGP-2encodes 64 to 67 kD proteins containing domains that
mRNA expression nearly 40% in cystic kidney. EGF mRNA was se-
function in nuclear localization, non-specific and se- verely diminished in cystic compared to normal kidney, but was in-
creased 12-fold in cystic kidney following c-myc ASO treatment. Allquence-specific DNA binding, and oligomerization [18].
of the northern blot hybridization studies were performed in duplicatec-Myc functions as a transcription factor that dimerizes
using different sets of RNAs. Representative autoradiographs as well
with other proteins and binds DNA [18, 19]. These heter- as methylene blue staining of 28S and 18S ribosomal RNA to ensure
equal loading and transfer of RNA are shown.odimeric DNA-binding complexes both activate and re-
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Fig. 3. Western blot analysis in 20 day-old control and c-myc ASO
treated C57BL/6J-cpk cystic kidney. The c-Myc and PCNA protein
levels were reduced 59% and 30%, respectively, in cystic kidney follow-
ing c-myc ASO treatment. All of the western blot hybridization studies
were performed in duplicate using different sets of total renal protein
samples. Glucocorticoid receptor was used as a control for loading
(based on unpublished data from R. Maser, personal communication).
press transcription of a number of genes [19]. Increased
expression of c-myc is seen in proliferating cells and
regulates cell growth, transformation, inhibition of dif-
ferentiation, and apoptosis [18, 19].
Fig. 4. Localization of c-Myc protein in 20 day-old control and c-mycRenal c-myc mRNA is overexpressed in all PKD mod-
ASO treated C57BL/6J-cpk cystic kidney. (a, b ) c-Myc protein is local-els examined [5, 6, 9, 11, 12]. In the kidney, c-Myc plays
ized to the nuclei of epithelial cells lining cystic (arrowheads) and
an important role in both apoptosis [12, 13, 20–23], and noncystic (*) tubules in control cystic kidney. (c ) After c-myc ASO
treatment, the c-Myc protein is reduced in the nuclei of epithelial cellsproliferation [12, 13, 22–24]. In vitro, overexpression of
lining the noncystic tubules, but unchanged in cystic tubules. a: 100X;c-myc promotes proliferation of cells in the presence of
b, c: 400X.
normal serum [18], but leads to apoptosis of cells in the
absence of growth factors [18, 25]. We hypothesized that
c-myc ASO treatment would result in a decrease in cellu-
lar proliferation and amelioration of the PKD. Renal c-myc may contribute to the abnormal behavior of both
epithelial cell hyperplasia appears to play an important cystic and noncystic tubules since some of the detrimen-
role in PKD initiation and progression [26, 27]. However, tal effects of this overexpression of c-myc were reduced
evidence of the effects of our ASO treatment on cell by ASO therapy.
proliferation has been equivocal. Western blot data sug- The use of phosphorodiamidate Morpholino oligomer
gests that the c-myc ASO treatment reduced prolifera- (PMO) chemistry to inhibit c-Myc in the cystic kidney
tion (reduced renal PCNA), however, renal histone H4 avoids possible adverse effects associated with the more
mRNA was not reduced by treatment. c-myc ASO treat- prevalent phosphorothioate oligonucleotides (PSOs). The
ment appears to reduce c-Myc protein, but primarily in internucleoside charges of the phosphorothioate analogs
the noncystic renal tubules. Since both cystic and noncys- are responsible for nonspecific effects through binding
tic tubules overexpress c-myc, both are exhibiting abnor- to cellular and extracellular proteins [28–30]. Nonspecific
malities. The effect of ASO treatment on cystic tubules interactions can lead to detrimental physiological effects
is suggested by the reduced renal size and less prominent in vivo including inhibition of the clotting cascade, activa-
cystic change. This c-myc ASO treatment also acts in tion of the complement cascade and severe hypotension
part by inhibiting the detrimental effects of c-myc over- [31–36]. Further, bolus injection of PSOs can lead to
expression on the noncystic tubules so they retain a more blockade of sympathetic tone due to antagonism of
normal function. This effect of c-myc ASO treatment on alpha-1 adrenergic receptors [37]. A second disadvan-
noncystic tubules is suggested by an increase in matura- tage of the PSO chemistry involves the RNase H mecha-
tion of the distal tubule and collecting duct as evinced nism of action. RNase H is a ubiquitous enzyme present
by increased EGF, and decreased SGP-2 mRNA concen- in the cell nucleus and cytoplasm in concentrations suffi-
cient to mediate the degradation of the RNA in an RNA/trations after treatment, respectively. Overexpression of
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